C
C2i Genomics
Offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA
About C2i Genomics
C2i Genomics is a biotech startup that has developed a groundbreaking blood test for detecting and quantifying residual cancer cells. This innovative technology addresses a significant gap in the current cancer treatment landscape, where tiny amounts of residual cancer cells may remain undetectable after surgery. C2i's ultra-sensitive test can identify these cells, enabling more precise personalized treatment and monitoring, reducing overall treatment costs, and accelerating drug development.
The company's technology is accessible globally, expanding the reach of precision cancer monitoring. This has multiple applications throughout a patient's treatment timeline, providing valuable data to inform treatment decisions and monitor progress.
C2i Genomics also offers its Minimal Residual Disease (MRD) monitoring and cancer Intelligence Platform to pharmaceutical and research partners. This platform can be used in clinical trials and research, providing accurate enrollment and highly sensitive and specific surrogate endpoints. This means that the platform can help speed up clinical trials by providing more precise and reliable data.
The company's executive team has a wealth of experience from military intelligence and leading biotech companies, including the New York Genome Center, Bristol-Myers Squibb, GlaxoSmithKline, Tempus, Foundation Medicine, and Amwell.
C2i Genomics operates in the biotech and healthcare market, serving clients such as healthcare providers, researchers, and pharmaceutical companies. Its business model revolves around providing its proprietary cancer detection and monitoring technology and services to these clients, generating revenue through service fees and partnerships.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 63.1/100
- Industry
- Health, Enterprise Software
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Oncology, Genetics and genomics, Precision Medicine, Spinout, Genome Engineering, Tech for Hospitals and Clinics, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2024 | $70M | $70M | Veracyte | ↗ |
| SERIES BOther financing | Apr 2021 | $100M | $400M | Silver Lake Partners · iGlobe Partners · LionBird · Alexandria Venture Investments | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for C2i Genomics is 360 monthly website visits, down 33.3% over the last three months. C2i Genomics's team declined 67.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A10 investors entered at this stage
Casdin Capital
The Mark Foundation for Cancer Research
Silver Lake Partners
iGlobe Partners
LionBird
Alexandria Venture Investments
Driehaus Capital Management
Gordon Asset Management
Section 32
Duquesne Family Office
Other known investors4 additional known investors
Cornell Tech
Cornell University
New York Genome Center
Veracyte
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about C2i Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See C2i Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.